Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 338 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Colloid Clear all
Terminated Phase 2 Interventional Accepts healthy volunteers

Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis

NCT00322296
View directory record Official record
Conditions
Parapsoriasis
Interventions
Bexarotene 1% gel
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Oct 23, 2026, 9:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Carbon-13 (13C)-Spirulina Platensis Gastric Emptying Breath Test (GEBT)

NCT01248221
View directory record Official record
Conditions
Dyspepsia
Interventions
[13C]-Spirulina platensis and 99mTc sulfur colloid
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Oct 23, 2026, 9:55 AM EDT
Terminated Not applicable Interventional Results available

Intravenous Fat Emulsions and Premature Infants

NCT01096446
View directory record Official record
Conditions
Hypertriglyceridemia, Hyperglycemia
Interventions
Intravenous Fat Emulsions
Drug
Lead sponsor
OSF Healthcare System
Other
Eligibility
1 Day to 2 Days
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 23, 2026, 9:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline

NCT04072146
View directory record Official record
Conditions
Healthy Subjects
Interventions
Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg, OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Oct 23, 2026, 9:55 AM EDT
Terminated Not applicable Interventional

PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.

NCT03502824
View directory record Official record
Conditions
Chronic Pressure Ulcers
Interventions
PuraPly® Antimicrobial Wound Matrix, SOC for Pressure Ulcers
Device · Other
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Lake Success, New York • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 23, 2026, 9:55 AM EDT
Active, not recruiting Phase 1 Interventional

QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT04898543
View directory record Official record
Conditions
Metastatic Solid Tumor
Interventions
M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B), N-803 (Cohort 2 part B), Apheresis collection of MNCs (part A)
Biological · Other
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
El Segundo, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 23, 2026, 9:55 AM EDT
Recruiting Early Phase 1 Interventional

Aprepitant for the Treatment of CLIFAHDD

NCT07845825
View directory record Official record
Conditions
CLIFAHDD, Congenital Contractures of the Limbs and Face, Hypotonia, and Developmental Delay, NALCN Channelopathy, Ataxia - Other, Neurodevelopmental Disorder (Diagnosis)
Interventions
Aprepitant Powder for Oral Suspension
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
6 Months and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 9:55 AM EDT
Terminated Not applicable Interventional Results available

Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer

NCT00070317
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage I Cervical Cancer
Interventions
Isosulfan Blue, Lymph Node Mapping, Lymphangiography, Methylene Blue, Radionuclide Imaging, Sentinel Lymph Node Biopsy, Technetium Tc-99m Sulfur Colloid, Therapeutic Conventional Surgery
Drug · Procedure · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 23, 2026, 9:55 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA

NCT04732468
View directory record Official record
Conditions
Covid19
Interventions
hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule)
Biological · Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
El Segundo, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 23, 2026, 9:55 AM EDT
Terminated Phase 4 Interventional Results available

Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis

NCT01115244
View directory record Official record
Conditions
Dermatitis Herpetiformis
Interventions
Dapsone gel, 5%
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 23, 2026, 9:55 AM EDT
Completed Phase 3 Interventional Results available

To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.

NCT02465632
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel, BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%, Placebo
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
13
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 23, 2026, 9:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Tetracaine 0.5% and Lidocaine 2% Jelly for Topical Phacoemulsification Cataract Surgery

NCT00827073
View directory record Official record
Conditions
Cataracts
Interventions
tetracaine 0.5%, Lidocaine 2% Jelly
Drug
Lead sponsor
Hermann Eye Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Oct 23, 2026, 9:55 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically

NCT07201376
View directory record Official record
Conditions
Non-Melanoma Skin Cancer (NMSC), Benign Skin Growth
Interventions
Ameluz 10% Topical Gel, Protoporphyrin IX
Drug · Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 23, 2026, 9:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

NCT01302847
View directory record Official record
Conditions
HIV Infections
Interventions
DTG film-coated tablets, DTG granules for suspension, DTG dispersible tablets
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Weeks to 17 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
17
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 23, 2026, 9:55 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluating the Human Immune Response to the JYNNEOS Vaccine

NCT06366672
View directory record Official record
Conditions
Vaccinia, Virus Diseases
Interventions
JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection, Phlebotomy, Research bronchoscopy, Skin punch biopsy, Bone marrow aspiration
Biological · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 9:55 AM EDT
Active, not recruiting Phase 1 Interventional

Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer

NCT03028311
View directory record Official record
Conditions
Metastatic Liver Carcinoma, Stage IV Liver Cancer, Stage IVA Liver Cancer, Stage IVB Liver Cancer
Interventions
Angiography, Computed Tomography, Planar Imaging, Radioembolization, Single Photon Emission Computed Tomography, Technetium Tc-99m Albumin Aggregated, Yttrium Y 90 Resin Microspheres
Procedure · Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 9:55 AM EDT
Completed Phase 3 Interventional Results available

Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage

NCT00647556
View directory record Official record
Conditions
Photoaging
Interventions
adapalene gel, 0.3%, tretinoin 0.05% emollient cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 23, 2026, 9:55 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns

NCT02148705
View directory record Official record
Conditions
Thermal Burns
Interventions
NexoBrid, Standard of Care (SOC), Gel Vehicle
Drug · Procedure
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years to 77 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
18
States / cities
Mobile, Alabama • Phoenix, Arizona • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 23, 2026, 9:55 AM EDT
Completed Phase 3 Interventional

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

NCT02865005
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone 5.0% Gel (SEEGPharm), Placebo, Dapsone 5.0% Gel (Allergan)
Drug · Other
Lead sponsor
Seegpharm S.A.
Industry
Eligibility
12 Years to 40 Years
Enrollment
2,361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
35
States / cities
Encino, California • Fullerton, California • La Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 23, 2026, 9:55 AM EDT
Completed Phase 4 Interventional Results available

Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis

NCT01154153
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial and/or Seasonal
Interventions
Placebo nasal spray, Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ), Claritin® Syrup
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 12 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Cypress, California • Stockbridge, Georgia • North Dartmouth, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Oct 23, 2026, 9:55 AM EDT
Completed Not applicable Interventional Results available

STOPAIN in the Treatment of a Single Migraine Attack

NCT01687101
View directory record Official record
Conditions
Migraine, Headache
Interventions
STOPAIN topical gel
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 23, 2026, 9:55 AM EDT
Completed Phase 4 Interventional Results available

Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes

NCT00907101
View directory record Official record
Conditions
P Acnes Colonization
Interventions
Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 23, 2026, 9:55 AM EDT
Completed Phase 1 Interventional

Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.

NCT02748902
View directory record Official record
Conditions
Verruca Vulgaris, Common Warts
Interventions
ingenol mebutate 0.05% gel
Drug
Lead sponsor
Neal D. Bhatia, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 23, 2026, 9:55 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis

NCT01287364
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
ciclesonide hydrofluoroalkane (HFA) nasal aerosol, mometasone nasal inhalation
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
6
States / cities
Mission Viejo, California • San Diego, California • North Dartmouth, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2012 · Synced Oct 23, 2026, 9:55 AM EDT